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Abstract
Protein engineering approaches are often a combination of rational design and directed evolution using display
technologies. Here, we test ‘‘loop grafting,’’ a rational design method, on three-finger fold proteins. These small reticulated
proteins have exceptional affinity and specificity for their diverse molecular targets, display protease-resistance, and are
highly stable and poorly immunogenic. The wealth of structural knowledge makes them good candidates for protein
engineering of new functionality. Our goal is to enhance the efficacy of these mini-proteins by modifying their
pharmacological properties in order to extend their use in imaging, diagnostics and therapeutic applications. Using the
interaction of three-finger fold toxins with muscarinic and adrenergic receptors as a model, chimeric toxins have been
engineered by substituting loops on toxin MT7 by those from toxin MT1. The pharmacological impact of these grafts was
examined using binding experiments on muscarinic receptors M1 and M4 and on the a1A-adrenoceptor. Some of the
designed chimeric proteins have impressive gain of function on certain receptor subtypes achieving an original selectivity
profile with high affinity for muscarinic receptor M1 and a1A-adrenoceptor. Structure-function analysis supported by
crystallographic data for MT1 and two chimeras permits a molecular based interpretation of these gains and details the
merits of this protein engineering technique. The results obtained shed light on how loop permutation can be used to
design new three-finger proteins with original pharmacological profiles.
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Introduction
Protein engineering can draw inspiration from architectural
motifs that have been selected and used in nature to support a large
diversity of biological functions. Peptide toxins from venomous
animals could be part of the answer. Indeed, although toxins exert
their neurotoxic, cardiotoxic or cytotoxic effect by interacting with
a large diversity of molecular targets, the number of protein
templates selected during the course of evolution to accomplish
such vast range of physiological effects appears to be rather limited
[1,2,3]. The three-finger toxin (3FT) family is widely represented
as structural motif, mainly in the Elapidae snake venoms,
supporting various biological functions [4,5]. This fold is
characterized by three adjacent loops rich in b-pleated sheets
emerging from a small globular core containing four invariant
disulfide bridges [6]. Despite the small number of residues in the
3FT motif, their targets are numerous and include: L-type calcium
channels, integrin receptors, cell membrane phospholipids, ace-
tylcholinesterase, nicotinic acetylcholine or muscarinic and
adrenergic receptors [5], making this template attractive in protein
engineering. Functional studies by site-directed mutagenesis have
identified the sites by which some of these toxins interact with their
respective targets. Examples are neurotoxins that interact with
muscular and/or neuronal subtypes of nicotinic acetylcholine
receptors [7,8,9] and with acetylcholinesterase [10]. Transfer of
small portions of sequence between an acetylcholinesterase
inhibitory toxin to a curaremimetic toxin has resulted in
a committal transfer of function [11]. The structure of the
modified toxin shows a replication of the loop conformation of the
parent [12]. Similarly, grafting the extremity of the central loop of
a neuronal nicotinic toxin on the scaffold of a muscular-type toxin
confers to it an improved neuronal activity [13]. More recently,
using a cDNA display strategy to produce a large peptide library,
Naimuddin and coworkers engineered a 3FT by randomizing
residues in the three loops in order to obtain modulators of
interleukin-6 receptor [14]. All these results emphasize the
structural and functional adaptability of the three-finger fold and
the ease with which it can support protein engineering.
Muscarinic toxins (MTs) were isolated and purified from the
venom of African mambas more than 20-years ago [15,16] while
the identification and purification of adrenergic toxins from
mamba or cobra venom occurred more recently [17,18,19].
Despite high primary structure identity, often greater than 55%,
muscarinic and adrenergic toxins exhibit distinct pharmacological
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example, MT7 acts as a highly potent and selective antagonist of
the M1 receptor subtype [24,25,26,27,28], through a very stable
interaction with the allosteric binding site on the M1 receptor [29].
On the other hand, the mode of interaction of MT1 with
muscarinic receptors is less precisely defined, but its selectivity
profile for M1 and M4 receptors has been clearly established
(review in [20,21]). Based on previous data reporting adrenergic
effects of MT1 in tissue preparations [30], the ability of various
MTs to interact with adrenoceptors was investigated, showing that
MT1 interacts efficiently with mAChRs and also with a1A- and
a2B-adrenoceptors [23].
The 23 sequence variations between MT7 and MT1 corre-
spond to residues equally distributed on the three loops of these
toxins (Fig. 1). ‘‘Loop grafting’’ has been used to construct seven
chimeric toxins to dissect how the affinity, selectivity and
functionality for the muscarinic and adrenergic receptors depend
on shuffling loops between various toxins. Three chimeras were
obtained by substituting loops of the MT7 toxin with the
corresponding loop from the MT1. These chimeras were named
MT7-1/1, MT7-1/2 and MT7-1/3, numbered for the respective
grafted MT1 loop. Given that grafts of the entire loop 2 had
enormous effects, this loop was separated into two distinct regions.
Two other chimeras were synthesized containing three modifica-
tions at the tip of loop 2 (MT7-1/2 tip) or four modifications at the
top (MT7-1/2 top), respectively. For sake of completion, two
further chimeras were synthesized. These were designed by
combining MT7-1/2 tip and MT7-1/3 (MT7-1/2 tip+3) or
MT7-1/1 and MT7-1/3 with two additional point mutations
found in the C-terminal portion of the MT1 sequence (MT7-1/
1+3; Fig. 1). The new designed toxins exhibit original selectivity
profiles.
The crystallographic structures of wild-type MT1 and of the
engineered chimeric toxins obtained in this study show that despite
local structural deviations, the overall integrity of the three-finger
fold structure is conserved and the intra-loop hydrogen-bonding
maintained. Binding experiments of the natural and engineered
toxins on different GPCRs reveal a significant gain in function on
a1A-adrenoceptor and hM4 muscarinic receptor. It cannot be
excluded that these results may have a broader general relevance
on a wider spectrum of GPCRs. This engineering study has
created novel ligands by combining pre-existing loops. Given the
lack of GPCR selective ligands, this approach offers an additional
strategy to fill this gap.
Results
Synthesis and Folding of Wild-Type and Modified Toxins
The muscarinic toxins, MT7 and MT1, have been synthesised
by the one step Fmoc solid phase peptide synthesis approach
previously described [25]. We have solved the problems previously
reported during the synthesis of the MT1 toxin consisting of
failures in the deprotection monitoring and lower couplings
because of local chain aggregation. These occurred in two regions;
the central part of the sequence (Val-32 - Tyr-35) and the N-
terminal end (Leu-1 - Ser-8). The solution was to replace Thr-13
and Thr-39, two residues introduced during the synthetic process
before the two critical regions, by a pseudo-proline residue. We
therefore incorporated the dimethyloxazolidine of the di-peptide
Ile-Thr at positions 12–13 and 38–39 during the synthesis. This
chemical modification disrupts peptide chain aggregation in the
Figure 1. Sequence alignment of the toxins MT7, MT1, MT3 and r-Da1a compared to the various chimeras. The grafted residues of MT1
loop 1 are shown in green with conserved residues in a lighter shade generating the chimera of MT7-1/1. For MT7-1/2, MT7-1/2tip and MT7-1/2top
the grafted residues of MT1 loop 2 are shown in cyan (top) and blue (tip) and the conserved residues in a lighter shade. For MT7-1/3, MT7-1/1+3 and
MT7-1/2tip+3 the grafted residues of MT1 loop 3 are shown in yellow with the conserved residues in a lighter shade. The two extra mutations on the
C-terminal section of MT7-1/1+3 that correspond to residues from MT1 are shown in magenta. Below the space-filling representation on the MT7
structure show the positioning of the grafted loops from MT1.
doi:10.1371/journal.pone.0039166.g001
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improvement during the synthesis of the different chimeric toxins.
The synthesis of MT7-1/2 top and MT7-1/3 were undertaken in
a similar manner as that described for MT7 using Fmoc amino
acids and the efficient coupling reagents HOAT or CL-HOBT/
DCCI. However, for the other chimeric toxins, the dipeptide Ile-
Thr was introduced using Fmoc-Ileu-Thr (Y
MeMepro)-OH at
positions 12–13 in the MT7-1/1 or MT7-1/1+3 and 38–39 in
MT7-1/2, MT7-1/2 tip and MT7-1/2 tip+3. A longer coupling
time was used for this reaction. During the synthesis of the
different toxins no failure in the deprotection monitoring was
observed. At the end of the synthesis, regeneration of the Thr from
the oxazolidine occurs during the course of the normal TFA-
mediated cleavage reaction and each toxin yielded a crude
mixture in which the main component corresponds to the reduced
form of each chimera toxin.
Folding of the different chimera toxins was achieved using the
experimental conditions that were successfully applied to the MT7
and MT1 toxins. An efficient and rapid folding process was
followed for MT7-1/1 and MT7-1/3 but not for MT7-1/2, MT7-
1/2tip and MT7-1/2top. To find out a common optimal refolding
condition, we screened different additives and various concentra-
tions of reduced and oxidized glutathione. The final optimized
refolding buffer containing 30% glycerol, 0.1 M Tris-HCl, 1 mM
EDTA, 1 mM GSH, 1 mM GSSG, pH 8 was used to prepare
large amounts of the different chimeras (refolding yield; 20–30%).
Amino acid composition and electro-spray mass analysis con-
firmed the purity and identity of the different proteins. The masses
were 7359.2 for MT7-1/1 (theoretical 7359.4), 7538.5 for MT7-
1/1+3 (theoretical 7538.6), 7443.3 for MT7-1/2 (theoretical
7443.5), 7440.2 for MT7-1/2tip (theoretical 7440.5), 7546.5 for
MT7-1/2tip+3 (theoretical 7546.6) 7475.2 for MT7-1/2top
(theoretical 7475.6) and, 7578.7 for MT7-1/3 (theoretical 7578.8).
The CD spectrum analysis of the MT7, MT1 and chimeric
toxins reveals a typical b-sheet signature in these toxins with the
maximum and minimum signals observed at 196 and 210 nm,
respectively (see Figure S1, Supporting Information). An addi-
tional distinct signature at 230 nm, previously reported for MT1
[25] and characteristic of the two substitutions Q29Y and R40W,
is also observed for MT7-1/2 and MT7-1/2 top. A similar effect
was also observed for erabutoxin, due to an aromatic residue at
position 29 [32].
Crystallization and Crystallographic Structure
Determination
Crystals of MT1 and MT7-1/1 toxins were obtained by sitting
drop vapor diffusion and MT7-1/3 by slow evaporation close to
48 mg/ml protein concentration. The crystallographic structures
of the MT7-1/1 and MT7-1/3 toxins were solved by molecular
replacement with the MT7 diiodo-Tyr51 (PDB code=2VLW)
[28] as a starting model while MT1 was solved using toxin r-Da1a
(unpublished) as starting model. The structures were refined to
1.3 A ˚, 1.39 A ˚ and 1.8 A ˚ resolution, respectively (Table S1). The
asymmetric unit of MT1 (PDB code =4DO8) is composed of two
toxins, an acetate and a thiocyanate ions, the latter ion, positioned
between the two molecules in the asymmetric unit, might be
important for the crystallization. The two molecules are virtually
identical and superimpose with a mean deviation of 0.32 A ˚ (rmsd
=0.74 A ˚) on all atoms and an rmsd 0.15 A ˚ on 256 main chain
atoms. The asymmetric unit of chimera MT7-1/1 (PDB code
=3FEV) consists of three toxins that superimpose well on each
other but with larger deviations compared to MT1 (rmsd between
chains A/B =0.88 A ˚; A/C =0.73 A ˚; B/C =1.10 A ˚ on all main
chain atoms). The major variations are at the tips of loops 2 and 3,
the region that was not manipulated. MT7-1/3 (PDB code
=3NEQ) counts two molecules in the asymmetric unit with an
rmsd of 1.47 A ˚ between the two molecules on all 207 main chain
atoms. The superimposition of the different copies of each toxin
infers that these structures are uniquely defined while retaining
a certain degree of flexibility. The canonical three-finger fold
structure comprising five b-strands forming a twisted b-sheet is
strictly abided to (Fig. 2a).
Structure Comparisons
The structures of the MT7 diiodo-Tyr51 (PDB code=2VLW),
MT1, MT7-1/1 and MT7-1/3 described here, were super-
imposed with COOT [33] and pyMOL to understand the
structural effect of loop grafting on the individual loops (Fig. 2)
and on the global superimposition of the various structures (see
Figure S2, Supporting Information). The loops with the MT1
sequence grafted onto the MT7 scaffold superimpose well on those
found on the parent toxin (Fig. 2). Loop 1 of each of the three
molecules in the asymmetric unit of MT7-1/1 superimposes
precisely on that of loop 1 of MT1 (Fig. 2b). The loop separates
from loops 2 and 3 as it does in MT1 but to a greater extent. The
comparison of loop 3 from each of the two molecules in the
asymmetric unit of MT7-1/3 compared to MT1 shows again an
excellent match (Fig. 2c). The comparisons of loop 2 from MT1
and MT7 shows that the backbone of this loop is conserved
between the two natural toxins, but the side chains adopt
a different orientation (Fig. 2d). The comparison of loop 2 from
chain A of MT7-1/3 with loop 2 of MT1 shows that the
replacement of loop 3 of MT7 for that of MT1 imposes
a reorientation of the side chains to match that of MT1 although
there is poor sequence identity (Fig. 2e).
MT1 superimposition onto MT7 by least-squares fit shows large
deviations in both the loops and in the sequence-conserved
disulphide-bridged scaffold leading to important differences when
the main chain atoms are compared (rmsd MT1 vs
MT7=3.2260.01 A ˚, depending on the molecule in the asym-
metric unit that are compared). A better match can be obtained by
not matching consecutive residues but only the secondary-
structure elements. Secondary-structure matching (SSM) [34] for
the MT1/MT7 comparison leads to a value of around 1.34 A ˚
where the matched residues have a reduced sequence identity of
only 66%. Given that loop 3 of MT1 is longer than that of MT7,
the least-squares fit method is also inappropriate. In supplemen-
tary figure S2 we use the relatively good conservation of the
conformation of loop 2 and its interaction with the second strand
of loop 3 to guide the overall structural superposition. This allows
for a visual rather than mathematical scoring of the alignment. To
better understand the comparison by the two methods we can
consider the superposition of MT1 with chimera MT7-1/3 that
counts the same number of residues (Fig. 1). By least-squares fit we
have an rmsd for MT1 vs MT7-1/3 of 2.8760.08 A ˚ while by
SSM the value falls to an rmsd of 0.89 A ˚ on 61 aligned residues
with a 79% sequence identity. The superimposition obtained by
matching only loop 2 and the second strand of loop 3 agrees better
with the SSM value (see Figure S2, Supporting Information).
Comparing by least-squares fit MT1 to chimera MT7-1/1 is less
reliable because of a difference in sequence length which gives an
rmsd between MT1 and MT7-1/1 of 2.3860.03 A ˚. By SSM the
rmsd remains high at 1.64 A ˚. This is mainly because the algorithm
aligns 64 residues instead of only 61 in the previous comparison
where 3 extra residues on loop 1 were omitted due to excessive
deviation. If MT7 is compared to chimera MT7-1/1, least-squares
gives an rmsd of 3.1360.02 A ˚ while by SSM gives 1.4 A ˚. In this
comparison SSM uses only 59 residues. The SSM superimposition
Three-Finger Fold Toxins Engineering
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residues matched with a 91.5% identity, in good agreement with
the SSM values (see Figure S2, Supporting Information).
Equilibrium Binding Studies of Wild-Type and Chimeric
Toxins to the hM1, hM4 Muscarinic Receptors and a1A-
Adrenoceptor
MT7 and MT1 toxins interact with muscarinic and adrenergic
receptors with an affinity of 34 pM and 24 nM for M1, 13 mM
and 310 nM for M4 and greater than 20 mM and 62 nM for a1A,
respectively. To identify the 3FT regions responsible for these
large differences in affinity which could be submitted to
engineering, we analyzed the impact of substitutions in each loop
of MT7 on its binding affinity on the different receptor subtypes.
The capacity of wild-type and chimeric toxins to inhibit the
binding of [
3H]-NMS to hM1 or hM4 membrane preparations
was measured (Fig. 3a, 3b), allowing the calculation of their pKi
(Table 1). Substitutions within loops 1 and 3 weakly affect the
toxin’s interaction with the hM1 receptor, corresponding to a 2-
fold decrease in affinity. In contrast, grafting the entire loop 2 of
MT1 into the MT7 scaffold (MT71/2) induces a drastic 400-fold
drop in affinity for the M1 receptor (Table 1). Interestingly,
a similar effect was observed with the MT7-1/2 top chimera with
only four modifications: R27K, Q29Y, F38I, and R40W.
Changing the tip of the central loop (MT71/2 tip chimera) affects
moderately toxin binding with a relatively low 7-fold decrease in
affinity. Moreover, combining these later substitutions (S32V,
M35Y and Y36S) with the grafting of loop 3, leading to the MT7-
1/2 tip+3 chimera, confirms the low impact of the modifications
introduced in these two regions of the toxin for the hM1
interaction. Finally, combining loops 1 and 3 substitutions with
two additional modifications in the C-terminal part (G59E, K65E)
(MT7-1/1+3) leads to a severe 360-fold decrease in affinity for the
hM1 receptor (Table 1).
On the hM4 receptor, only MT1 was able to displace
completely the radiotracer in the range of concentrations used
Figure 2. Schematic representation of MT7 (green), MT1 (gold) and chimeras MT7-1/1 (magenta) and MT7-1/3 (cyan). a) Toxins
superimposed globally on each other. The largest deviations are observed on loop 1 and the tips of the various loops. b) Chimera MT7-1/1
superimposed on MT1 on loop 1 shown in stick representation. c) Chimera MT7-1/3 superimposed on MT1 on loop 3 showing that although loop 2
remains entirely that of MT7 and that there are strong interactions between loop 2 and loop 3, loop 3 maintains strictly its conformation as on MT1.
d) As shown by the superimpositions of loop 2 from MT1 and MT7, although the backbone matches well, to maintain the interaction between loop 2
and loop 3 and the conformation of loop 3 as in MT1, the side chain orientations on loop 2 of MT7 require adaptive changes. e) The side chain
orientations of loop 2 of chimera MT7-1/3 resemble those of loop 2 of MT1 although the sequence is that of MT7.
doi:10.1371/journal.pone.0039166.g002
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for all the other toxins suffice to give a good approximation of their
affinity constants (Table 1). The affinity of MT7 for hM4 is very
low (pKi: 4.8760.06), approximately 40-fold less than that of
MT1 (pKi: 6.5060.04). Modifications introduced in the MT7-1/
1, MT7-1/1+3 and MT7-1/2 top chimeras affected only weakly
the affinity for the hM4 receptor (less than 2-fold decrease),
whereas the MT7-1/2, MT7-1/2 tip and MT7-1/3 increase the
affinity by 4- to 5-fold. It is worth noting that the gain in affinity
obtained by combining MT7-1/2 tip and MT7-1/3, in the MT7-
Figure 3. Inhibition of [
3H]-NMS binding to hM1 and hM4 receptors by wild-type MT7, MT1 and chimera toxins. Binding experiments
were performed by incubating hM1 (A) or hM4 (B) membrane fractions of receptor with [
3H]-NMS (0.5 nM) and varying concentrations of toxin at
room temperature and overnight. The total specific binding in each experiment was 15006300 cpm. The results are expressed as the ratio of the
specific [
3H]-NMS binding measured with (B) or without toxin (Bo). All experiments were performed at least three times in duplicate.
doi:10.1371/journal.pone.0039166.g003
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increase for the hM4 receptor (Table 1).
Equilibrium binding experiments with [3H]-Prazosin show that
MT1 and MT7 toxins interact with a1A-adrenoceptor with
relatively high (pKi: 7.2160.16) and very low affinity (pKi
.4.7), respectively. A 200-fold increase in affinity was obtained
by the independent grafting of either loop 1 or 3, enough to
elevate the affinity of MT7 to the level of MT1 (Table 1; Fig. 4).
The partial or total insertion of the loop 2 was ineffective.
Remarkably, a 6000-fold increase in affinity compared to MT7
was achieved on the a1A-adrenoceptor by grafting a combination
of loops 1 and 3 (MT7-1/1+3; pKi: 8.4760.08), corresponding to
a 20-times affinity increase relative to MT1 (Table 1).
Discussion
Becausetheyareresistanttodegradation,permissivetomutations
and tolerant to large insertions or deletions, three-finger fold toxins
(3FT) have been largely exploited by snakes to support various toxic
functions in their venoms [5]. These characteristics make the three-
finger fold template suitable for protein engineering [11,13,14].
Structural knowledge to drive the 3FT engineering is still lacking in
thecontextof3FT-GPCRscomplexesalthoughmoleculardynamics
Table 1. Affinity constants of wild-type MT7, MT1 and chimeric toxins for M1, M4 muscarinic receptors and a1A-adrenoceptor.
M1 M4 a1A
pKi
Ki tox/Ki MT7 loss of
function pKi
Ki MT7/Ki tox gain
of function pKi
Ki MT7/Ki tox.gain of
function
MT7 10.4760.04 1 4.8760.06 1 .4.7 1
MT7-1/1 10.1660.05 2 .4.7 ,0.67 7.1060.11 .252
MT7-1/2 7.8660.02 406 5.5960.04 5.3 .4.7 1
MT7-1/3 10.0460.11 2.6 5.5160.08 4.4 6.9760.09 .187
MT7-1/2tip 9.5760.13 7.5 5.6060.08 5.4 .4.7 1
MT7-1/2top 7.6260.07 706 .4.7 ,0.67 .4.7 1
MT7-1/2tip+3 9.8360.02 4.4 6.5860.01 52 6.3660.01 .46
MT7-1/1+3 7.9160.02 362 .4.7 ,0.67 8.4760.08 .5900
MT1 7.6260.04 706 6.5060.04 43 7.2160.16 .325
doi:10.1371/journal.pone.0039166.t001
Figure 4. Inhibition of [
3H]-Prazosin binding to a1A-adrenoceptor by MT7, MT1 and chimeric toxins. Binding experiments were
performed by incubating a1A-AR membrane fractions of receptor with [
3H]-Prazosin (1.5 nM) and varying concentrations of toxin at room
temperature and overnight. The results are expressed as the ratio of the specific [
3H]-Prazosin binding measured with (B) or without toxin (Bo). All
experiments were performed at least three times in duplicate.
doi:10.1371/journal.pone.0039166.g004
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thatcouldbepermissivetomodification[35].Usingtheinteractionof
3FT toxins with muscarinic or adrenergic receptors as a model
system, we have addressed this question by a loop grafting strategy
producing seven chimeric toxins by chemical synthesis. These
chimeras are the results of the transfer of MT1 loops into the MT7
template (Fig. 1).
The structural impact of loop grafting was analyzed by X-ray
crystallography. The three-dimensional structures of chimeras
MT7-1/1 and MT7/1-3 were determined and compared to those
of the natural toxins MT1 and MT7, previously reported
[28].?The comparison shows which features are transferred from
parent to chimera and which features are more variable and could
give rise to the new functionality. Given the high resolution of the
structures and the presence of multiple copies of each toxin in the
crystal asymmetric unit, it leaves no doubt that the amino acid
sequence determines the conformation of the individual loops and
that the loop conformation is transferred together with the loop.
The structures provide irrefutable evidence that for loops 1 and 3
grafted from MT1 onto the scaffold of MT7 retain their original
conformation (Fig. 2a, 2b). Another invariable is that the backbone
conformation of loop 2 is well conserved between MT7 and MT1,
although the sequence is not. Loop grafting preserves the overall
three-finger structure in all chimeric toxins. The spatial relation-
ship of the grafted loops with the remaining part of the structure is
variable. The grafted loop 1 of chimera MT7-1/1 preserves its
structure as in MT1 but does not adopt the same relationship with
loop 2 as in MT1 nor keep the relationship found between loop 1
and loop 2 of MT7. Thus a new toxin with novel properties is
created by the grafting. The situation with loop 3 is different
because of the conserved interaction between loop 2 and the
second strand of loop 3. To preserve the interaction we have
observed that the side chain orientations on the top part of loop 2
tend to conform to those from the parent toxin. Indeed, in chimera
MT7-1/3 the side chains on loop 2 execute a concerted rotation
and adopt conformers that match closely those on MT1 loop 2.
This observation is linked to the change from Arg-40 at the top of
loop 2 of MT7 to Trp in MT1. The flexible Arg side chain can
adopt the same side chain orientation as the Trp (Fig. 2e) and
because such orientation is not compatible with that of the other
side chains on the loop, the side chains are forced to change. The
effect that this could have on receptor binding is unpredictable.
These movements are important in explaining the effect of grafting
of loop 2, in particular the top of the loop. The tip of this loop is
relatively independent of the rest of the toxin in MT7 but in MT1
with the longer loop 3 this is no longer the case (see Figure S3,
Supporting Information). This is important when comparing
toxins with different lengths of loop 3 (Fig. 1).
Since GPCRs are among the targeted receptors for the three-
finger fold class of toxins, it can be envisaged that the scaffold
formingthebasisoftheirdiversitycouldbeengineeredtoyieldnovel
ligands, some of which would be selective for GPCRs not yet
targetedinnature.Toevaluatethishypothesis,wehaveapproached
the process of diversification by the ‘‘loop grafting’’ strategy and we
have produced 3FT chimeric toxins with new pharmacological
profiles towards muscarinicand adrenergicreceptors, withaffinities
that sometimes surpass those of the two parent toxins.
Grafting the entire MT1 loop 2 (chimera MT7-1/2) onto the
MT7 template provokes a large decrease in affinity of the toxin for
hM1 receptor (400-fold), a weak increase for hM4 (5-fold) and no
effect on a1A-adrenoceptor (Table 1). Comparison of the affinities
of the MT7-1/2top and MT7-1/2tip chimeras on the three
receptors with those of the MT7-1/2 toxin confirms the lack of
effect of the modifications introduced in this region on the a1A-
adrenoceptor binding and suggests that the drastic loss in function
on hM1 and the moderate gain in function on hM4 are mainly
associated with the top and the tip of loop 2, respectively. Indeed,
with only four substitutions compared to MT7 (R27K, Q29Y,
F38I and R40W), MT7-1/2top reaches an affinity for hM1 equal
to that of MT1 while all chimeras have a higher affinity. Of these
four substitutions, the F38I mutation involves a 2-fold loss in
affinity [36] and the R27K substitution is relatively conservative,
suggesting that the MT7-specific residues, Gln-29 and Arg-40
might play an important role in the hM1 receptor interaction. The
R40W is important for the relationship between loop 2 and loop 1
(Fig. 2e, see Figure S3, Supporting Information). Nevertheless,
previous results using punctual alanine modification have shown
the crucial role of residues at the tip of loop 2, such as Arg-34 and
Tyr 30, in the MT7-hM1 interaction [25,29]. Conservation of
these residues in MT7-1/2tip chimera may explain the relative
high affinity of this toxin and suggests that the three substitutions
included in this chimera (S32V, M35Y, Y36S) induced the
moderate affinity decrease for hM1 receptor (7-fold). Similarly,
these substitutions play a positive role in the hM4 recognition, as
shown by the 5-fold increase in affinity observed on this receptor
(Table 1). Thus, loop 2 is highly critical in the picomolar affinity of
the MT7-hM1 interaction, weakly involved in the hM4 recogni-
tion and plays no role in the a1A-adrenoceptor binding.
On hM1 receptor, substitutions of MT7 loops 1 and 3 by those
of MT1 (chimeras MT7-1/1 and MT7-1/3) have no significant
impact on the toxin affinity (Table 1), suggesting that the seven
modifications associated with each of these substitutions were not
involved in the high affinity of the MT7-hM1 interaction. Even if
these results do not exclude a complementary role of the toxin
loops 1 and 3 in the MT7-hM1 receptor interaction, as proposed
on the structural model of this complex [29], they are consistent
with previous results obtained with punctual alanine modifications,
reporting that some modifications in loops 1 and 3 of MT7 have
weak or no effect on the toxin’s affinity for the hM1 receptor [28].
While loop 1 transfer has no significant effect on the toxin affinity
for hM4, a moderate gain of function (5-fold) is observed with the
grafting of loop 3 (Table 1). Notably, a two orders of magnitude
increase in affinity for the a1A-adrenoceptor is achieved for
chimeras MT7-1/1 and MT7-1/3 by the grafting of loop 1 or 3.
These toxins are characterized by an affinity close to that of MT1
for the a1A-adrenoceptor.
Combining some of the previous grafting in an attempt to
optimize our engineering, leads to new chimeric toxins with
affinities which surpasses that both of natural parents. For
example, the weak gain in function on hM4 receptor consecutive
to the loop 3 or loop 2tip substitutions is largely enhanced on the
MT7-1/2tip+3 which combines both modifications. Thus, a 50-
fold gain in function is observed with this chimera (Table 1). In
nature, the MT3 toxin has evolved to reach an affinity of 2 nM for
the hM4 receptor [23,37]. Comparing its sequence with those of
MT7, MT1, MT7-1/2tip+3 (Fig. 1) reveals that the chimera
comes close to matching the MT3 sequence. The most interesting
changes are localized at the tip of loops 2 and 3. These are
ValMT1/IleMT3/SerMT7-32, TyrMT1&MT3/MetMT7-35, SerMT1/
ThrMT3/TyrMT7-36 at the tip of the loop 2 and ProMT1&MT3/
AlaMT7-49, AsnMT1&MT3/TyrMT7-51, ThrMT1-55/SerMT3-54/
ValMT7-54 and ArgMT1-57/HisMT3-56/AsnMT7-56 at the tip of
the loop 3. The MT7 specific residues, Ser-32, Met-35, Tyr-36,
Ala-49, Tyr-51, Val-54 and Asn-56 are likely to be responsible for
the exceptional selectivity of this toxin for hM1 relative to the
hM4. Loop 3 would appear to be responsible for the receptor
subtype selectivity. More strikingly, the simultaneous grafting of
the loops 1 and 3 of MT1 on the MT7 scaffold provokes on a1A-
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with separate permutations. Thus, the MT7-1/1+3 chimera
reaches an affinity which is 6000 times greater that MT7 and
even 20 times more potent than MT1 on this receptor subtype
(3.4 nM; Table 1). The major role of the loop 1 in this interaction
is coherent with the large sequence identity (80–90%) in this
region between MT1 and the two most potent toxins that target
this receptor subtype: MT3 (1.6 nM) and r-Da1a (0.3 nM) (Fig. 1)
[17,23]. Since loop 3 of MT3 and r-Da1a are identical, the
differences in their affinity for a1A-adrenoceptor are probably due
to sequence variations on loop 1. It is interesting to note that the
chimera MT7-1/1+3 is built by loops 1 and 3 of MT1 grafted
simultaneously on the MT7 skeleton with the additional G59E-
K65E modifications present on MT1 (Fig. 1, see Figure S3,
Supporting Information). This chimera is MT1-like with only the
central loop of MT7 grafted onto the MT1 template and displays
an affinity for hM1 receptor twice that of MT1. The transposition
of loop 2 from MT1 to MT7 (chimera MT7-1/2) or from MT7 to
MT1 (chimera MT7-1/1+3) leads to the same affinity on hM1.
This corresponds to a 2-fold gain compared to MT1 but a 400-fold
loss compared to MT7. This suggests first that the two Glu
insertions and more particularly the C-terminal charge inversion
would be involved in the decrease in affinity of the MT7-hM1
interaction and secondly that the relationship between the loops
and not just loop 2 is important in the interaction with the hM1
receptor. This result is structurally very important as it highlights
how selectivity can be modulated through loop grafting. The
MT7-1/1+3 toxin possesses a unique pharmacological profile
among all the muscarinic and adrenergic toxins with a high affinity
for hM1 and a1A receptors and no interaction with hM4.
In conclusion, the loop transfer engineering methodology
described here is an effective means of creating new functionality
onto the 3FT scaffold by connecting together a relatively small
number of LEGO-like blocks. By this approach, we were able to
produce chimeric toxins with affinity towards receptors that
surpass that of the two parent toxins, thus creating ligands with
unique pharmacological profiles. Since only seven chimeric toxins
have been chemically synthesized starting from loops from just two
toxins (MT1 and MT7; Fig. 1), the gain in function is very
encouraging, considering that the engineering database from
which loops could be selected is vast. Furthermore, functional
regions that have been identified can later be improved by display
methodology. Comparison of the chimeric toxins sequences
developed in this study with those of natural toxins like MT3
and r-Da1a reveals certain similarities, suggesting that a ‘‘loop
permutation-like’’ strategy might happen in nature to diversify the
toxins functions to respond to modifications of the snake’s
environment. This hypothesis can be correlated with the recently
proposed ASSET strategy, suggesting that an accelerated segment
switch in exons in 3FT may alter their molecular targets selection
by inducing change or gain of functions [38,39]. Since the three-
finger toxin fold was known to interact with diverse targets
including various biogenic amine GPCRs, our data are likely to be
of broad general relevance.
Materials and Methods
Materials
[
3H]-N-Methylscopolamine ([
3H]-NMS; 78 Ci/mmol) and 7-
Methoxy-[
3H]-prazosin ([
3H]-prazosin; 85 Ci/mmol) were ob-
tained from PerkinElmer (Courtaboeuf, France). Atropine, N-
methylscopolamine and prazosin were purchased from Sigma-
Aldrich (St Quentin-Fallavier, France).
Peptide Synthesis
Assembly of the different chimeric proteins were performed on
a standard Applied Biosystems 433 peptide synthesizer (Applied
Biosystems, France) and carried out using the stepwise solid-phase
method with dicyclohexyl-carbodiimide/HOAT (1-hydroxy-aza-
benzotriazole) or 6-Cl-HOBT (6-chloro-1-hydroxybenzotriazole)
as coupling reagents and N-methyl pyrrolidone as solvent. Fmoc-
protected amino acids were used with the following side-chain
protections: t-butyl ester (Glu,Asp), t-butyl ether (Ser, Thr, Tyr),
trityl (Cys, His, Asn, Gln), 2,2,5,7,8-pentamethyl-chromane-6-
sulfonyl (Arg), t-butyloxy-carbonyl (Trp). The Fmoc-pseudoproline
dipeptide, introduced at different positions in the chimera toxins
was Fmoc-Ileu-Thr (Y
MeMepro)-OH. The MT7-MT1- chimera
toxins were assembled on a Fmoc-Glu(OtBu)-Wang resin (loading:
0.5 mMol/g) or Fmoc-Lys(Boc)-Wang resin (loading: 0.55 mMol/
g). The different syntheses were run on a modified version of the
Applied Biosystems standard 0.1 mmole small-scale program
using 0.05 mmole of each resin. This program achieves UV
monitoring of the deprotection step. When the deprotection is too
slow after two and/or three successive deprotections of 3 min, it
automatically extends the deprotection time by 20 min and the
coupling time (normal coupling: 30 min or 60min in case of
pseudoproline dipeptide) by an extra 30 min. After each coupling,
the resin was acetylated by a mixture of 5% acetic anhydride, 6%
2,4,6-collidine in DMF. At the end of the synthesis the peptide-
resins were treated with trifluoroacetic acid (9 ml), triisopropylsilan
(0.5 ml), and 0.5 ml distilled water. The peptides were then
cleaved from the resin and the protecting groups were removed
from amino acid side-chains. After two hours of incubation, the
mixture was filtered in cold tert-butyl methyloxide and centrifuged
three times. The precipitates were dissolved in a solution of 10%
acetic acid and lyophilized. The toxins were purified by reverse
phase HPLC using a Discovery BioWidepore C5 column
(Supelco,PA, USA) (250610 mm) with a gradient of 40 to 60%
of solvent B in 40 min, (A: 0.1% TFA in H2O, B: 60% acetonitrile
and 0.1% TFA in H2O) The flow rate was 4 ml/min and the
detection was followed at 280 and 214 nm.
Optimization of Disulfide Bond Formation, Purification
and Characterization
The reduced synthetic and chimera toxins were subjected to an
oxidative reaction in 0.1 M Tris, 1mM EDTA buffer (pH 7.8)
containing 0.5 M guanidine hydrochloride in the presence of
reduced (GSH) and oxidized (GSSG) glutathione in a molar ratio
of 1/10/100 peptide/GSSG/GSH at a concentration of
0.05 mg/ml as described elsewhere (12) or submitted to a refolding
screening procedure. In this case, a reduced-denatured toxin, was
screened against 40 different refolding conditions, a combination
of 8 buffers (100 mM Tris-Cl, 1 mM EDTA pH 8 with or without
100 mM NaCl, or 30% glycerol or 0,25% triton X100 or 100 mM
NDSB-256 or 0.05% PEG3500 (w/v) or 0.5 M Gnd-Cl or 0.5 M
Arg) and 5 concentrations of the redox couple of reduced
glutathione (GSH) and oxidized glutathione (GSSG): 10/1 mM,
5/1 mM, 1/1 mM, 5/0.5 mM, 1/0.5 mM. To minimize the
adsorption of protein on to the vessel’s surface the refolding was
carried out in a microsorb eppendorf tube of 1 ml. Each sample
was reduced for 2 h at 37uC in 6 M guanidine-HCl, 10 mM
dithiothreitol (DTT), 50 mM Tris, pH 8 denaturing buffer.
Refolding was initiated by a 1/200 fold rapid dilution in ice cold
refolding buffer to a final concentration of 20 mg/ml and a final
volume of 1 ml followed by incubation at 4uC for 72 h. Refolding
efficiency was evaluated by integrating the surface of the peak
corresponding to the refolded form of the protein after analytical
HPLC separation. Typically, the pH of each sample was lowered
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autosampler (Waters 717plus) connected to an HPLC chain
(Waters 600) and a photodiode array detector (Waters 996). Fast
separation was performed on a Chromolith SpeedRod, RP18e,
50–4.6 mm column (Merck, Darmstadt,Germany) by means of
a 10 min linear gradient of acetonitrile in 0,1% (by vol.)
trifluoroacetic acid from 25 to 35% at a flow rate of 4 ml/min,
detection 214 nm.
Large scale refolding was performed by diluting the reduced
protein 200 fold in the optimized refolding buffer namely 100 mM
Tris-HCl, 1 mM EDTA, 30% glycerol, 1 mM GSH, 1 mM
GSSG pH 8 to a final concentration of 0.1 mg/ml and then
incubated at 4uC for 72 h. After acidification the purification of
the refolded toxins were performed on a Discovery BioWidepore
C5 column (Supelco, PA, USA) (250610 mm) with a gradient of
40 to 60% of solvent B in 40 min, (A: 0.1% TFA in H2O, B: 60%
acetonitrile and 0.1% TFA in H2O) The flow rate was 4 ml/min
and the detection was followed at 280 and 214 nm. Finally, each
protein was analytically characterized on analytical reversed-phase
HPLC a Discovery BioWidepore C5 column (Supelco,PA, USA)
(10064.5 mm) with a gradient of 40 to 60% of solvent B in
40 min, (A: 0.1% TFA in H2O, B: 60% acetonitrile and 0.1%
TFA in H2O). The flow rate was 1 ml/min and the detection was
followed 214 nm. For the amino acid analysis, the hydrolysates
obtained after acid hydrolysis in a sealed vial were heated at 120uC
in the presence of 6 N HCl for 16 h and analysed using an
Applied Biosystems model 130A automatic analyzer equipped
with an online 420A derivatizer for the conversion of the free
amino acid into phenyl thiocarbamoyl. Mass determination was
performed on a Nermag spectrometer coupled to an analytical
(Brandford) electrospray source. The concentrations of the
different toxins were evaluated spectrometrically.
Circular Dichroism Analysis
CD spectra were recorded on a Jasco J-815 CD spectrometer.
Measurements were routinely performed at 20uC in 0.1 cm path-
length quartz cells (Hellma, Paris, France) with a peptide
concentration of 10
–5 M in water. Spectra were recorded in the
186 to 260 nm wavelength range. Each spectrum represents the
average of at least three spectra.
Crystallization
The crystallization of the MT7 wild-type toxin in its diiodo-
Tyr51 derivative had been reported previously [28]. Briefly,
lyophilized synthetic toxin was re-suspended at 5 mg/ml in 0.02%
azide, 50 mM sodium acetate, pH 4.6. The reservoir solution used
was 1.25 M ammonium sulfate, 90 mM sodium citrate, and 10%
methyl pentanediol (MPD), pH 5.5. Similarly, lyophilized syn-
thetic toxin MT1 was re-suspended at 8.3 mg/ml in 0.02% azide,
50 mM sodium acetate, pH 5.5 and crystallized by sitting drop
vapor diffusion over a reservoir consisting of 36% mono-methyl
polyethylene glycol 2,000 (MPEG 2K), 450 mM NaCl, 90 mM
KSCN, 100 mM imidazole-HCl, pH 7.5. Crystals appeared after
1 month. No cryoprotectant was needed for flash-cooling given
the high MPEG concentration used to crystallize the toxin. The
chimera MT7-1/1 was prepared from 1.3 mg of lyophilized
synthetic toxin dissolved in 50 mM Na acetate, pH 5.5, with
0.02% azide to yield a 5 mg/ml solution. Screening for
crystallization was carried out by sitting drop vapor diffusion at
20uC in a cooled incubator using 4 selected conditions from the
‘‘Stura’’ screens [40] (Molecular Dimensions) and the conditions
that had yielded crystals for the wild type MT7. Conditions that
yielded crystals were further refined. The crystals used for data
collection were grown from 1.2 M ammonium sulfate, 90 mM
sodium citrate, with 4% MPD, 6% propanol at pH 5.5. The
crystals were transferred to a cryo-solution consisting of 1.5 M
ammonium sulfate, 75 mM sodium citrate, pH 5.5, 25% glycerol
and 5% MPD. After a short solvent exchange step the crystals
were cryo-cooled in liquid ethane. Chimera MT7-1/2 was found
to be less soluble than MT7-1/1, tended towards filamentous
aggregation. A similar problem had been encountered with the
first batch of toxin MT1 from which crystals could not be obtained
given the limited quantities available insufficient to carry out
a more complete screen. Chimeric toxin MT7-1/3 was prepared
from 0.48 mg resuspended in 0.02% azide, 50 mM sodium
acetate at pH 5.5 to yield a 5 mg/ml solution. Needle crystals of
this chimera were obtained from 1.02 M ammonium sulfate,
50 mM sodium citrate, 1% MPD at pH 5.5 using the same
conditions as for MT7-1/1 without any need for screening. Better
crystals were obtained later by the slow evaporation method over
a period of 3 months at 4uC in a laboratory refrigerator. The
method consists in allowing moisture to escape slowly over a long
period of time. This can be done by loosening the cap of an
eppendorf tube containing the protein. However, we used a more
reproducible method that consists in replacing the screw cap by
one from a different manufacturer and screwing in the cap tightly.
Because the specifications of the two manufacturers differ, this still
allows water vapor to leak out at a rate that is compatible with
crystallization while it is difficult to evaluate the rate of vapor
escape from a loosened cap. When the crystals were harvested, the
effective concentration of the protein was estimated from the
decrease in sample volume to be 48 mg/ml. The crystals were
stabilized in two steps: first in a solution consisting of 0.96–1.26 M
ammonium sulfate, 65 mM sodium citrate with 5% MPD, pH 5.5
over a period of at least one day and then in 80% saturated lithium
sulfate before cryo-cooling in liquid ethane.
Data Collection and Crystal Structure Determination
Data for the all the crystals were collected at the European
Synchrotron Radiation Facility (ESRF). As previously reported
[28], data to 1.38 A ˚ resolution were collected on beamline ID14-2
from a crystal cryo-cooled in 80% saturated Li2SO4 as
a cryoprotectant. Data for MT7-1/1 were collected on beamline
ID14-4 at 100uK from single crystal to 1.3 A ˚ resolution. The
crystal was found to belong to the space group P212121 with cell
parameters 27.1 A ˚,7 2 A ˚, 89.4 A ˚ and three molecules in the
asymmetric unit (Table S1). For MT7-1/3 data extending to
1.39 A ˚ resolution were collected on beamline ID29. The crystals
also belong to the space group P212121 but with different cell
parameters: 25.8 A ˚, 56.6 A ˚, 80.7 A ˚; with two molecules in the
asymmetric unit. The data were processed using MOSFLM [41]
and reduced using programs from the CCP4 suite of programs.
Molecular replacement was carried out with MOLREP [42] using
the diiodo-MT7 (PDB code=2VLW) as the starting model. After
restrained refinement using REFMAC [43] the amino acid
differences between the two loops were corrected according to
the sequence. Density fitting and refinement were carried out with
the aid of electron density maps (omit sA-weighted 2Fo- Fc and
Fo-Fc) calculated and displayed using the XtalView [44] suite of
programs and COOT [33]. Stereochemical analysis of the final
refined model was checked with the validation tools in COOT.
Waters were checked with phenix.refine [45]. Refinement statistics
are detailed in Table S1 (MT1 R =19.3% Rfree=23.4%); (MT7-
1/1 R =21.4% Rfree =23.3%); (MT7-1/3 R =21.2%
Rfree=24.9%). The figures were made with PYMOL from
DeLano Scientific LLC (The pyMOL Molecular Graphics
System. DeLano Scientific, San Carlos, CA, USA).
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The coordinates and structure factors for the chimeric toxins
have been deposited in the RCSB Protein Data Bank with the
following ID codes: MT1:4DO8; MT7-1/1:3FEV; MT7-1/
3:3NEQ.
CHO Cells and Membrane Preparation
Profs. P. O. Couraud & A. D. Strosberg (ICGM, Paris, France)
kindly provided CHO cells stably expressing the cloned human
muscarinic M1 and M4 receptors. The cells were grown in plastic
Petri dishes (Falcon) which were incubated at 37uCi na n
atmosphere of 5% CO2 and 95% humidified air in Ham F12
medium pre-complemented with L-glutamine and bicarbonate
(Sigma) supplemented with 10% fœtal calf serum and 1%
penicillin/streptomycin (Sigma). At 100% confluence, the medium
was removed and the cells were harvested using Versen buffer
(PBS +5 mM EDTA). They were washed with ice-cold phosphate
buffer and centrifuged at 1700 g for 10 min (4uC). The pellet was
suspended in ice-cold buffer (1 mM EDTA, 25 mM Na
phosphate, 5 mM MgCl2, pH 7.4) and homogenized using an
Elvehjem-Potter homogenizer (Fisher Scientific Labosi, Elancourt,
France). The homogenate was centrifuged at 1700 g for 15 min
(4uC). The sediment was resuspended in buffer, homogenized and
centrifuged at 1700 g for 15 min (4uC). The combined super-
natants were centrifuged at 35000 g for 30 min (4uC) and the
pellet was suspended in the same buffer (0.1 ml/dish). Protein
concentrations were determined according to the Lowry method
using bovine serum albumin as standard. The membrane
preparations were aliquoted and stored at –80uC. a1A-adreno-
ceptor cDNA inserted into the prK5 vector was kindly provided by
Michael Brownstein (Craig Venter Institute, Rockville, MD). COS
cells grown at 37uC under 5% CO2 in Dulbecco’s modified Eagle’s
medium containing 10% fetal calf serum, 1% penicillin and 1%
glutamine (Sigma-Aldrich, St Quentin-Fallavier, France). At 80%
confluence, cells were transfected using calcium phosphate pre-
cipitation to transiently express the a1A-adrenoceptor. After 48h
incubation at 37uC, cells were harvested and the membranes were
prepared as previously described [27].
Equilibrium [
3H]-NMS and [
3H]-Prazosin Binding Assays
The effect of MT7, MT1 toxins and various chimeric toxins on
the equilibrium binding of [
3H]-NMS for muscarinic M1 and M4
receptors and [
3H]-Prazosin for a1a-adrenoceptor were de-
termined with equilibrium inhibition binding experiments. For
[
3H]-NMS binding, membrane protein concentrations, adjusted
so no more than 10% of added radio-ligand was specifically bound
(around 1500–2000 cpm), were incubated in PBS-BSA at 25uC for
18 to 22 h, with varying concentrations of toxin and [
3H]-NMS
(0.5 nM), in a final assay volume of 300 ml. Non-specific binding
was determined in the presence of 50 mM atropine. The reaction
was stopped by addition of 3 ml of ice-cold buffer (PBS)
immediately followed by filtration through Whatman GF/C glass
fiber filters pre-soaked in 0.5% polyethylenimine. The filters were
washed once again with 3 ml ice-cold buffer (PBS), dried and the
bound radioactivity was counted by liquid scintillation spectrom-
etry. Binding experiments with [
3H]-Prazosin (1.5 nM) were
performed in a 100 mL reaction mix at room temperature in
buffer composed of 50 mM Tris-HCl, pH 7.4, 10 mM MgCl2,
1 g/L BSA. Incubation was stopped by filtration through 96 GF/
C filter plates pre-incubated with 0.5% polyethylenimine. 25 mLo f
Microscint 0 were added onto each dry filter and the radioactivity
was quantified on a TopCount beta counter (PerkinElmer,
Courtaboeuf, France). Non specific binding were measured in
presence of prazosin (10 mM). Each experiment was done in
duplicate at least three times.
Data Analysis
The binding data from individual experiments (n$3) were
analyzed by nonlinear regression analysis using Kaleidagraph 4.0
(Synergy Software, Reading, PA). After subtraction of the non-
specific binding and normalization, data obtained with [
3H]-NMS
and [
3H]-prazosin were analyzed using the Hill equation to
estimate the IC50 and the slope factor, nH, of the inhibition curve.
The affinities of toxins in inhibiting the binding of radiotracers,
expressed as pKi, were calculated from the IC50 values by applying
the Cheng-Prusoff correction. Following the results obtained on
the[
3H]-NMS dissociation experiments on M1 receptor, high-
lighting the allosteric behaviour of MT7, MT7-1/1and MT7-1/3
toxins, the allosteric ternary complex model [46] was used to
analyze the data on the effect of these toxins on the specific
binding of the orthosteric radioligand [3H]-NMS.
Supporting Information
Figure S1 Overall far-UV CD spectra pattern of the
different toxins and chimera. The CD spectra were
monitored in water, at 20uC with a peptide concentration of
10 mM.
(PDF)
Figure S2 Schematic representation of MT7 (green),
MT1 (gold) and chimeras MT7-1/1 (magenta) and MT7-
1/3 (cyan) superimposed on each other on loop 2. a) The
superimposition of MT1 onto MT7 shows important deviation in
both loops and in the sequence conserved disulphide-bridged
scaffold but good conservation of the conformation of loop 2 and
its interaction with the second strand of loop 3. This interaction is
conserved in the chimeras. b) Chimera MT7-1/1 superimposes
well on MT7 except for the grafted loop 1 which adopts the
conformation and orientation seen in MT1. c) Chimera MT7-1/3
superimposes well on MT1 except for loop 1 which maintains the
conformation and orientation seen in MT7. d) Chimera MT7-1/3
superimposes poorly on MT7. It maintains the interaction
between loops 1 and 2 and but this implies that the disulphide-
bridged scaffold adopts an orientation rotated with respect to the
first two loops.
(PDF)
Figure S3 Space-filling representation of MT7 and
MT1. The residues from loop 1 colored in green (conserved in
lighter shade), residues from loop 2 in blue (tip) and cyan (top) with
the conserved residues in lighter shades, loop 3 in yellow
(conserved in lighter shade) and the C-terminal residue in
magenta. a) Front view of MT7 showing the interacting residues
from the three loops. b) Back view of MT7 showing the
interacting residues from the three loops and the C-terminal
residue. c) Front view of MT7 with the residues from loop 2 top
removed to show the lack of interactions between the other
elements of the toxin assembly apart from the interaction of the C-
terminal residue with loop 1. d) Front view of MT1 showing that
the overall shape of the toxin differs substantially from that of
MT7. e) Back view of MT1 showing variations in most elements,
except the tip that maintains its orientation relative to the rest of
the toxin as in MT7. f) With the top of loop 2 removed, MT1
shows that its C-terminal residue mediates an interaction between
loops 1 and 3 and that the tip of loop 2 is stabilized by the longer
loop 3.
(PDF)
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